HOME >> BIOLOGY >> NEWS
Columbia researcher identifies cellular defect that may contribute to autism

NEW YORK, NY, January 27 The causes of autism have long remained a mystery, but new research from Columbia University Medical Center has identified, for the first time, how a cellular defect may be involved in the often crippling neurological disorder.

The research, which is published in today's issue of Science, examines how a defect in neuroligin genes may contribute to autism. Neuroligins are components of synapses, which connect individual neurons in the brain. The researchers found that the loss of neuroligins perturbs the formation of neuronal connections and results in an imbalance of neuronal function. This imbalance provides an explanation for the neurodevelopmental defects in autistic children.

"Understanding the cellular defects that may underlie autism-spectrum disorders represents an important step towards the goal of providing therapies," said Peter Scheiffele, Ph.D., assistant professor of physiology and cellular biophysics at Columbia University Medical Center, and principal investigator on the study.

A defect in the neuroligin genes had previously been observed in autistic patients, but its functional significance was not yet understood. Scheiffele's study showed that in rat neurons without any neuroligin, connections between neurons are altered in a way that is strikingly similar to those found in autistic children.

Each neuron in the brain receives many different inputs some are excitatory and signal the neuron to fire, and some are inhibitory and signal the neuron to stop firing. Scheiffele's research team found that neuroligin genes are responsible for regulating the balance between excitatory and inhibitory synaptic function. A defect in neuroligin leads to a selective loss in inhibitory function and thereby impairs the fine-tuning of neuronal connectivity, a neurological problem that is understood to play a role in autism.

"There is much we still don't know about how neurons con
'"/>

Contact: Craig LeMoult
cel2113@columbia.edu
212-305-0820
Columbia University Medical Center
27-Jan-2005


Page: 1 2

Related biology news :

1. Columbia University Medical Center awarded $3 million to drive Alzheimers genetics research
2. Columbia scientists determine 3-dimensional structure of cells fuel gauge
3. Columbia University licenses next-generation DNA sequencing technology
4. New bird discovered on unexplored Columbian mountain
5. Columbia University Medical Center receives major new NIH Clinical Science investment funds
6. Columbia University awards 2006 Horwitz Prize to biologist who explained gene transcription
7. Columbia University receives $16.9 million NIEHS award to study arsenic in ground water
8. Contaminants linked to sturgeon decline in Columbia river
9. Columbia University Medical Center researchers discover potential mechanism for tumor growth
10. UF, Columbia scientists closer to new cancer detection method
11. Columbia University awards 2005 Horwitz Prize to Israeli structural biologist

Post Your Comments:
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)... March 10, 2015   Tute Genomics , pioneer ... selected by next-generation sequencing company PrimBio Research Institute ... and targeted gene panel interpretation. PrimBio, a ... the most current technologies to support the work of ... company offers two types of exome sequencing services: 1) ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
(Date:3/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... platform company serving the global pharmaceutical, biotechnology, and ... New Drug (IND) application for WuXi MedImmune,s novel ... accepted for review by the China Food and ... 2012, MedImmune, the global biologics research and development ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... that after dealing with certain matters, including the appointment ... held on March 26, 2015 (the "Meeting") was adjourned, ... 8, 2015 at 11:00 a.m. ( Toronto ... been changed from that previous disclosed. The Meeting will ...
(Date:3/26/2015)... , March 26, 2015 PAREXEL ... global clinical research organization , announced ... definitive agreement to acquire all of the ... a leading provider of specialized pharmacovigilance services, ... the collection, detection, assessment, monitoring, and prevention ...
(Date:3/25/2015)... market is one of the most attractive in the ... plus a growing economy and increasing government investment in ... The Russian market is set to grow at twice ... estimates around 10-15% annually reaching an approximate market value ... Cross Green Cross provides total healthcare solutions ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
Cached News: